Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
DOI: 10.1042/bj2820091 Youssef A et al
This is the first clinical trial testing this novel treatment class on top of standard of care including empagliflozin in people with chronic kidney disease (CKD), which affects more than 850 million people worldwide
Liu W, Jalewa J, Sharma M, Li G, Li L, Holscher C
27 May 2016
The mitochondrial targeting drug SkQ1 attenuates the progression of post- traumatic osteoarthritis through suppression of mitochondrial oxidative stress
Bacteria linked to reactive arthritis include: Salmonella Campylobacter Shigella Yersinia Chlamydia Typical joints are the knee, ankle, and foot
US$ 20.31
US$ 28.16
US$ 25.57
US$ 22.94
US$ 20.79
US$ 24.54
US$ 28.85
